Aileron Therapeutics Inc (NASDAQ:ALRN) Expected to Post Earnings of -$0.28 Per Share

Wall Street analysts expect Aileron Therapeutics Inc (NASDAQ:ALRN) to report ($0.28) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Aileron Therapeutics’ earnings. Aileron Therapeutics reported earnings of ($0.48) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 41.7%. The firm is expected to issue its next earnings results on Friday, April 3rd.

According to Zacks, analysts expect that Aileron Therapeutics will report full year earnings of ($1.27) per share for the current financial year, with EPS estimates ranging from ($1.31) to ($1.22). For the next year, analysts forecast that the business will post earnings of ($0.99) per share, with EPS estimates ranging from ($0.99) to ($0.98). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Aileron Therapeutics.

Aileron Therapeutics (NASDAQ:ALRN) last issued its earnings results on Thursday, November 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05).

A number of analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Aileron Therapeutics in a research report on Monday, September 30th. Zacks Investment Research raised Aileron Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $4.00.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its position in Aileron Therapeutics by 179.6% in the second quarter. BlackRock Inc. now owns 49,485 shares of the company’s stock worth $36,000 after acquiring an additional 31,787 shares in the last quarter. Virtu Financial LLC raised its holdings in shares of Aileron Therapeutics by 195.0% during the 3rd quarter. Virtu Financial LLC now owns 66,946 shares of the company’s stock valued at $45,000 after purchasing an additional 44,253 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Aileron Therapeutics by 261.6% during the 2nd quarter. Vanguard Group Inc. now owns 333,005 shares of the company’s stock valued at $240,000 after purchasing an additional 240,910 shares in the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

Shares of NASDAQ:ALRN opened at $0.81 on Thursday. The company has a current ratio of 4.12, a quick ratio of 4.12 and a debt-to-equity ratio of 0.21. Aileron Therapeutics has a 1 year low of $0.40 and a 1 year high of $2.60. The business has a fifty day simple moving average of $0.59 and a 200 day simple moving average of $0.60.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Further Reading: What economic reports are most valuable to investors?

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.